Knockdown of cullin 3 inhibits progressive phenotypes and increases chemosensitivity in cholangiocarcinoma cells

Pratummanee,Kandawasri; Kerdkumthong,Kankamol; Roytrakul,Sittiruk; Tantimetta,Phonprapavee; Runsaeng,Phanthipha; Saeheng,Sompop; Obchoei,Sumalee

doi:10.3892/mmr.2024.13322

Knockdown of cullin 3 inhibits progressive phenotypes and increases chemosensitivity in cholangiocarcinoma cells

Authors:
- Kandawasri Pratummanee
- Kankamol Kerdkumthong
- Sittiruk Roytrakul
- Phonprapavee Tantimetta
- Phanthipha Runsaeng
- Sompop Saeheng
- Sumalee Obchoei
View Affiliations

Affiliations: Department of Biochemistry, Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hatyai, Songkhla 90110, Thailand, Functional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumtani 12120, Thailand
Published online on: September 3, 2024 https://doi.org/10.3892/mmr.2024.13322
Article Number: 198
Copyright: © Pratummanee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma (CCA) is an extremely aggressive malignancy arising from the epithelial cells lining the bile ducts. It presents a substantial global health issue, with the highest incidence rates, ranging from 40‑100 cases/100,000 individuals, found in Southeast Asia, where liver fluke infection is endemic. In Europe and America, incidence rates range from 0.4‑2 cases/100,000 individuals. Globally, mortality rates range from 0.2‑2 deaths/100,000 person‑years and are increasing in most countries. Chemotherapy is the primary treatment for advanced CCA due to limited options from late‑stage diagnosis, but its efficacy is hindered by drug‑resistant phenotypes. In a previous study, proteomics analysis of drug‑resistant CCA cell lines (KKU‑213A‑FR and KKU‑213A‑GR) and the parental KKU‑213A line identified cullin 3 (Cul3) as markedly overexpressed in drug‑resistant cells. Cul3, a scaffold protein within CUL3‑RING ubiquitin ligase complexes, is crucial for ubiquitination and proteasome degradation, yet its role in drug‑resistant CCA remains to be elucidated. The present study aimed to elucidate the role of Cul3 in drug‑resistant CCA cell lines. Reverse transcription‑quantitative PCR and western blot analyses confirmed significantly elevated Cul3 mRNA and protein levels in drug‑resistant cell lines compared with the parental control. Short interfering RNA‑mediated Cul3 knockdown sensitized cells to 5‑fluorouracil and gemcitabine and inhibited cell proliferation, colony formation, migration and invasion. In addition, Cul3 knockdown induced G₀/G₁ cell cycle arrest and suppressed key cell cycle regulatory proteins, cyclin D, cyclin‑dependent kinase (CDK)4 and CDK6. Bioinformatics analysis of CCA patient samples using The Cancer Genome Atlas data revealed Cul3 upregulation in CCA tissues compared with normal bile duct tissues. STRING analysis of upregulated proteins in drug‑resistant CCA cell lines identified a highly interactive Cul3 network, including COMM Domain Containing 3, Ariadne RBR E3 ubiquitin protein ligase 1, Egl nine homolog 1, Proteasome 26S Subunit Non‑ATPase 13, DExH‑box helicase 9 and small nuclear ribonucleoprotein polypeptide G, which showed a positive correlation with Cul3 in CCA tissues. Knocking down Cul3 significantly suppressed the mRNA expression of these genes, suggesting that Cul3 may act as an upstream regulator of them. Gene Ontology analysis revealed that the majority of these genes were categorized under binding function, metabolic process, cellular anatomical entity, protein‑containing complex and protein‑modifying enzyme. Taken together, these findings highlighted the biological and clinical significance of Cul3 in drug resistance and progression of CCA.

View Figures

View References

1	Kirstein MM and Vogel A: Epidemiology and risk factors of cholangiocarcinoma. Visc Med. 32:395–400. 2016. View Article : Google Scholar : PubMed/NCBI
2	Blechacz B: Cholangiocarcinoma: Current knowledge and new developments. Gut Liver. 11:13–26. 2017. View Article : Google Scholar : PubMed/NCBI
3	Kodali S, Connor AA, Brombosz EW and Ghobrial RM: Update on the screening, diagnosis, and management of cholangiocarcinoma. Gastroenterol Hepatol (N Y). 20:151–158. 2024.PubMed/NCBI
4	Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, La Vecchia C and Negri E: Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 71:104–114. 2019. View Article : Google Scholar : PubMed/NCBI
5	Adeva J, Sangro B, Salati M, Edeline J, La Casta A, Bittoni A, Berardi R, Bruix J and Valle JW: Medical treatment for cholangiocarcinoma. Liver Int. 39 (Suppl 1):S123–S142. 2019. View Article : Google Scholar
6	Rizvi S and Gores GJ: Pathogenesis, diagnosis and management of cholangiocarcinoma. Gastroenterology. 145:1215–1229. 2013. View Article : Google Scholar
7	Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, et al: Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial. JAMA. 308:147–156. 2012. View Article : Google Scholar : PubMed/NCBI
8	Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, et al: Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan. Br J Cancer. 103:469–474. 2010. View Article : Google Scholar : PubMed/NCBI
9	Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
10	Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, Rodrigues CMP, Lozano E, Mancarella S, Segatto O, et al: Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 39:43–62. 2019. View Article : Google Scholar : PubMed/NCBI
11	Sarikas A, Hartmann T and Pan ZQ: The cullin protein family. Genome Biol. 12:2202011. View Article : Google Scholar : PubMed/NCBI
12	Kamitani T, Kito K, Nguyen HP and Yeh ET: Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J Biol Chem. 272:28557–28562. 1997. View Article : Google Scholar : PubMed/NCBI
13	Zhang S, Yu Q, Li Z, Zhao Y and Sun Y: Protein neddylation and its role in health and diseases. Signal Transduct Target Ther. 9:852024. View Article : Google Scholar : PubMed/NCBI
14	Wang P, Song J and Ye D: CRL3s: The BTB-CUL3-RING E3 ubiquitin ligases. Adv Exp Med Biol. 1217:211–223. 2020. View Article : Google Scholar : PubMed/NCBI
15	Cheng J, Guo J, Wang Z, North BJ, Tao K, Dai X and Wei W: Functional analysis of Cullin 3 E3 ligases in tumorigenesis. Biochim Biophys Acta Rev Cancer. 1869:11–28. 2018. View Article : Google Scholar : PubMed/NCBI
16	Kim B, Nam HJ, Pyo KE, Jang MJ, Kim IS, Kim D, Boo K, Lee SH, Yoon JB, Baek SH and Kim JH: Breast cancer metastasis suppressor 1 (BRMS1) is destabilized by the Cul3-SPOP E3 ubiquitin ligase complex. Biochem Biophys Res Commun. 415:720–726. 2011. View Article : Google Scholar : PubMed/NCBI
17	Grau L, Luque-Garcia JL, González-Peramato P, Theodorescu D, Palou J, Fernandez-Gomez JM and Sánchez-Carbayo M: A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness. PLoS One. 8:e533282013. View Article : Google Scholar : PubMed/NCBI
18	Yuan WC, Lee YR, Huang SF, Lin YM, Chen TY, Chung HC, Tsai CH, Chen HY, Chiang CT, Lai CK, et al: A Cullin3-KLHL20 ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell. 20:214–228. 2011. View Article : Google Scholar : PubMed/NCBI
19	Zhou J, Zhang S, Xu Y, Ye W, Li Z, Chen Z and He Z: Cullin 3 overexpression inhibits lung cancer metastasis and is associated with survival of lung adenocarcinoma. Clin Exp Metastasis. 37:115–124. 2020. View Article : Google Scholar : PubMed/NCBI
20	Kerdkumthong K, Roytrakul S, Songsurin K, Pratummanee K, Runsaeng P and Obchoei S: Proteomics and bioinformatics identify drug-resistant-related genes with prognostic potential in cholangiocarcinoma. Biomolecules. 14:9692024. View Article : Google Scholar : PubMed/NCBI
21	Wattanawongdon W, Hahnvajanawong C, Namwat N, Kanchanawat S, Boonmars T, Jearanaikoon P, Leelayuwat C, Techasen A and Seubwai W: Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. Int J Oncol. 47:398–410. 2015. View Article : Google Scholar : PubMed/NCBI
22	Kerdkumthong K, Chanket W, Runsaeng P, Nanarong S, Songsurin K, Tantimetta P, Angsuthanasombat C, Aroonkesorn A and Obchoei S: Two recombinant bacteriocins, rhamnosin and lysostaphin, show synergistic anticancer activity against gemcitabine-resistant cholangiocarcinoma cell lines. Probiotics Antimicrob Proteins. 16:713–725. 2024. View Article : Google Scholar : PubMed/NCBI
23	Johansson C, Samskog J, Sundström L, Wadensten H, Björkesten L and Flensburg J: Differential expression analysis of Escherichia coli proteins using a novel software for relative quantitation of LC-MS/MS data. Proteomics. 6:4475–4485. 2006. View Article : Google Scholar : PubMed/NCBI
24	Thorsell A, Portelius E, Blennow K and Westman-Brinkmalm A: Evaluation of sample fractionation using micro-scale liquid-phase isoelectric focusing on mass spectrometric identification and quantitation of proteins in a SILAC experiment. Rapid Commun Mass Spectrom. 21:771–778. 2007. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, et al: UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 25:18–27. 2022. View Article : Google Scholar : PubMed/NCBI
27	Tang Z, Kang B, Li C, Chen T and Zhang Z: GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019. View Article : Google Scholar : PubMed/NCBI
28	Pontén F, Jirström K and Uhlen M: The Human Protein Atlas-a tool for pathology. J Pathol. 216:387–393. 2008. View Article : Google Scholar : PubMed/NCBI
29	Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P, et al: The STRING database in 2021: Customizable protein-protein networks and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 49:D605–D612. 2021. View Article : Google Scholar : PubMed/NCBI
30	Mi H, Muruganujan A, Ebert D, Huang X and Thomas PD: PANTHER version 14: More genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 47:D419–D426. 2019. View Article : Google Scholar : PubMed/NCBI
31	Ge SX, Jung D and Yao R: ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinform. 36:2628–2629. 2020. View Article : Google Scholar
32	Bulatov E and Ciulli A: Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: Structure, assembly and small-molecule modulation. Biochem J. 467:365–386. 2015. View Article : Google Scholar : PubMed/NCBI
33	Chen RH: Cullin 3 and its role in tumorigenesis. Adv Exp Med Biol. 1217:187–210. 2020. View Article : Google Scholar : PubMed/NCBI
34	Genschik P, Sumara I and Lechner E: The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): Cellular functions and disease implications. EMBO J. 32:2307–2320. 2013. View Article : Google Scholar : PubMed/NCBI
35	Chen HY and Chen RH: Cullin 3 ubiquitin ligases in cancer biology: Functions and therapeutic implications. Front Oncol. 6:1132016. View Article : Google Scholar : PubMed/NCBI
36	Haagenson KK, Tait L, Wang J, Shekhar MP, Polin L, Chen W and Wu GS: Cullin-3 protein expression levels correlate with breast cancer progression. Cancer Biol Ther. 13:1042–1046. 2012. View Article : Google Scholar : PubMed/NCBI
37	Dong M, Qian M and Ruan Z: CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein. J Immunother Cancer. 10:e0052702022. View Article : Google Scholar : PubMed/NCBI
38	Dorr C, Janik C, Weg M, Been RA, Bader J, Kang R, Ng B, Foran L, Landman SR, O'Sullivan MG, et al: Transposon mutagenesis screen identifies potential lung cancer drivers and CUL3 as a tumor suppressor. Mol Cancer Res. 13:1238–1247. 2015. View Article : Google Scholar : PubMed/NCBI
39	Feng Y, Zhao M, Wang L, Li L, Lei JH, Zhou J, Chen J, Wu Y, Miao K and Deng CX: The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations. Cell Death Dis. 15:342024. View Article : Google Scholar : PubMed/NCBI
40	Zhao M, Quan Y, Zeng J, Lyu X, Wang H, Lei JH, Feng Y, Xu J, Chen Q, Sun H, et al: Cullin3 deficiency shapes tumor microenvironment and promotes cholangiocarcinoma in liver-specific Smad4/Pten mutant mice. Int J Biol Sci. 17:4176–4191. 2021. View Article : Google Scholar : PubMed/NCBI
41	Li X, Yang KB, Chen W, Mai J, Wu XQ, Sun T, Wu RY, Jiao L, Li DD, Ji J, et al: CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression. Autophagy. 17:4323–4340. 2021. View Article : Google Scholar : PubMed/NCBI
42	Zeng R, Tan G, Li W and Ma Y: Increased expression of cullin 3 in nasopharyngeal carcinoma and knockdown inhibits proliferation and invasion. Oncol Res. 26:111–122. 2018. View Article : Google Scholar : PubMed/NCBI
43	Howley BV, Mohanty B, Dalton A, Grelet S, Karam J, Dincman T and Howe PH: The ubiquitin E3 ligase ARIH1 regulates hnRNP E1 protein stability, EMT and breast cancer progression. Oncogene. 41:1679–1690. 2022. View Article : Google Scholar : PubMed/NCBI
44	Mao X, Gluck N, Chen B, Starokadomskyy P, Li H, Maine GN and Burstein E: COMMD1 (copper metabolism MURR1 domain-containing protein 1) regulates Cullin RING ligases by preventing CAND1 (Cullin-associated Nedd8-dissociated protein 1) binding. J Biol Chem. 286:32355–32365. 2011. View Article : Google Scholar : PubMed/NCBI
45	Zhu T, Peng X, Cheng Z, Gong X, Xing D, Cheng W and Zhang M: COMMD3 expression affects angiogenesis through the HIF1α/VEGF/NF-κB signaling pathway in hepatocellular carcinoma in vitro and in vivo. Oxid Med Cell Longev. 2022:16555022022. View Article : Google Scholar : PubMed/NCBI
46	Huang W, Mei J, Liu YJ, Li JP, Zou X, Qian XP and Zhang Y: An analysis regarding the association between proteasome (PSM) and hepatocellular carcinoma (HCC). J Hepatocell Carcinoma. 10:497–515. 2023. View Article : Google Scholar : PubMed/NCBI
47	Sun L, Wu C, Ming J, Guo E, Zhang W, Li L and Hu G: EGLN1 induces tumorigenesis and radioresistance in nasopharyngeal carcinoma by promoting ubiquitination of p53 in a hydroxylase-dependent manner. J Cancer. 13:2061–2073. 2022. View Article : Google Scholar : PubMed/NCBI
48	Gulliver C, Hoffmann R and Baillie G: The enigmatic helicase DHX9 and its association with the hallmarks of cancer. Future Sci OA. 7:FSO6502020. View Article : Google Scholar : PubMed/NCBI
49	Bielli P, Pagliarini V, Pieraccioli M, Caggiano C and Sette C: Splicing dysregulation as oncogenic driver and passenger factor in brain tumors. Cells. 9:102019. View Article : Google Scholar : PubMed/NCBI
50	Mi H, Muruganujan A, Casagrande JT and Thomas PD: Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 8:1551–1566. 2013. View Article : Google Scholar : PubMed/NCBI
51	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
52	Thomas PD: The Gene Ontology and the meaning of biological function. Methods Mol Biol. 1446:15–24. 2017. View Article : Google Scholar : PubMed/NCBI
53	Esteve-Puig R, Bueno-Costa A and Esteller M: Writers, readers and erasers of RNA modifications in cancer. Cancer lett. 474:127–137. 2020. View Article : Google Scholar : PubMed/NCBI
54	Hu H, Hu W, Guo AD, Zhai L, Ma S, Nie HJ, Zhou BS, Liu T, Jia X, Liu X, et al: Spatiotemporal and direct capturing global substrates of lysine-modifying enzymes in living cells. Nat Commun. 15:14652024. View Article : Google Scholar : PubMed/NCBI
55	Wilkinson E, Cui YH and He YY: Context-dependent roles of RNA modifications in stress responses and diseases. Int J Mol Sci. 22:19492021. View Article : Google Scholar : PubMed/NCBI